Related Experiment Video

Updated: Aug 9, 2026

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.8K

Changes in glutamic oxaloacetic transaminase 2 during rat physiological and pathological cardiomyocyte hypertrophy

Xin Liu1, Xiaolu Li2, Haotan Zhou3

  • 1Department of Pediatric Cardiac Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. 18811563661@163.com.

BMC Cardiovascular Disorders
|December 5, 2023
PubMed

Insights

Glutamic oxaloacetic transaminase (GOT) levels differ in rat heart muscle growth. GOT2 protein increased in normal growth but decreased in pathological hypertrophy, suggesting a regulatory role in heart disease.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Physiological and pathological cardiomyocyte hypertrophy are key in congenital heart disease.
  • Glutamic oxaloacetic transaminase (GOT) indicates myocardial injury.
  • Investigates GOT changes during rat cardiomyocyte hypertrophy.

Purpose of the Study:

  • To examine GOT mRNA, activity, and GOT2 protein levels during physiological and pathological cardiomyocyte hypertrophy in rats.
  • To understand GOT's role in ventricular hypertrophy associated with congenital heart disease.

Main Methods:

  • RNA-sequencing and colorimetric assays for GOT mRNA and activity.
  • Western blotting and immunofluorescence for GOT2 protein.
  • Histological methods (H&E, WGA) for cardiomyocyte morphology.

Main Results:

  • GOT mRNA, activity, and GOT2 protein increased with age-related physiological hypertrophy in juvenile rats.
  • GOT2 protein levels decreased in hypoxia-induced pathological hypertrophy.
  • Significant differences in GOT2 expression correlate with hypertrophy type.

Conclusions:

  • GOT2 may play a regulatory role in both physiological and pathological myocardial hypertrophy in rats.
  • Reduced GOT2 levels might contribute to pathological hypertrophy and subsequent heart failure.
  • Findings suggest GOT2 as a potential therapeutic target for heart conditions.
Abstract

Keywords:
Congenital heart diseaseGlutamic oxaloacetic transaminasePathological cardiomyocyte hypertrophyPhysiological cardiomyocyte hypertrophy

More Related Videos

Magnetic Adjustment of Afterload in Engineered Heart Tissues09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

5.9K
Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

1.5K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...